Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Detecting Anal and Genital Human Papillomavirus Infection and Squamous Intraepithelial Lesions in HIV-Positive Patients Enrolled in AIDS Cancer Clinical Trials

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2014 by AIDS Malignancy Clinical Trials Consortium
Sponsor:
Collaborators:
The EMMES Corporation
Information provided by (Responsible Party):
AIDS Malignancy Clinical Trials Consortium
ClinicalTrials.gov Identifier:
NCT00695422
First received: June 7, 2008
Last updated: September 16, 2014
Last verified: September 2014
  Purpose

RATIONALE: Diagnostic procedures, such as anal swab collection, digital rectal examination, and anal endoscopy and biopsy, may help find and diagnose anal and genital human papillomavirus infection and squamous intraepithelial lesions and help doctors plan better treatment.

PURPOSE: This clinical trial is studying ways to detect anal and genital human papillomavirus infection and squamous intraepithelial lesions in HIV-positive patients enrolled in an AIDS cancer clinical trial.


Condition Intervention
Aids-related Malignancies
Lymphoma
Precancerous Condition
Sarcoma
Genetic: polymerase chain reaction
Other: cytology specimen collection procedure
Other: histological technique
Procedure: colposcopic biopsy

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: A Companion Protocol to Evaluate Anogenital Human Papillomavirus (HPV) Infection and Anogenital Squamous Intraepithelial Lesions (ASIL) in Subjects Participating in AMC Clinical Trials

Resource links provided by NLM:


Further study details as provided by AIDS Malignancy Clinical Trials Consortium:

Primary Outcome Measures:
  • Activity of pharmacotherapeutic agents being investigated in AIDS Malignancy Clinical Trials (AMC) against anogenital human papillomavirus (HPV) infection or anogenital squamous intraepithelial lesions (ASIL) [ Time Frame: Baseline, every 6 months while on parent protocol, treatment discontinuation on parent protocol, final visit on parent protocol ] [ Designated as safety issue: No ]
  • Cervical HPV infection and cervical/vulvovaginal disease in women participating in AMC clinical trials [ Time Frame: Baseline, every 6 months while on parent protocol, treatment discontinuation on parent protocol, final visit on parent protocol ] [ Designated as safety issue: No ]
  • Changes in cervical HPV infection and cervical/vulvovaginal disease after treatment on AMC studies [ Time Frame: Baseline, every 6 months while on parent protocol, treatment discontinuation on parent protocol, final visit on parent protocol ] [ Designated as safety issue: No ]
  • Changes in anal HPV types present [ Time Frame: Baseline, every 6 months while on parent protocol, treatment discontinuation on parent protocol, final visit on parent protocol ] [ Designated as safety issue: No ]
  • Frequency of ASIL [ Time Frame: Baseline, treatment discontinuation on parent protocol, final visit on parent protocol ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA

Blood specimens, anal cytology and biopsy of any lesions observed, cervical cytology and biopsy of any lesions observed.


Estimated Enrollment: 15
Study Start Date: May 2008
Estimated Study Completion Date: May 2015
Estimated Primary Completion Date: May 2015 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Specimen Collection
Blood collection, anal cytology and biopsy of observed lesions. Additional cervical cytology and biopsy for females.
Genetic: polymerase chain reaction
PCR for HPV DNA detection, performed on specimens collected at baseline, every 6 months while on parent protocol, treatment discontinuation on parent protocol, final visit on parent protocol.
Other: cytology specimen collection procedure
Detection of HPV-associated neoplasia at baseline, every 6 months while on parent protocol, treatment discontinuation on parent protocol, final visit on parent protocol.
Other: histological technique
Detection of HPV-associated neoplasia at baseline, treatment discontinuation on parent protocol, final visit on parent protocol.
Procedure: colposcopic biopsy
Where observed during HRA, collection of tissue for detection of HPV-associated neoplasia at baseline, treatment discontinuation on parent protocol, final visit on parent protocol.

Detailed Description:

OBJECTIVES:

Primary

  • To determine if various pharmacotherapeutic agents investigated in primary AIDS Malignancy Clinical Trials (AMC) for diseases other than human papillomavirus (HPV)-associated neoplasia have any preliminary evidence of activity against anogenital HPV infection or anogenital squamous intraepithelial lesions (ASIL) in HIV-positive patients participating in these trials.
  • To describe changes in the types of anal HPV present and the prevalence of ASIL in patients treated on these studies.
  • To evaluate cervical HPV infection and cervical/vulvovaginal disease in HIV-positive women participating in these trials.
  • To describe changes in cervical HPV infection and cervical/vulvovaginal disease in these women after undergoing various study treatments.

OUTLINE: This is a multicenter study.

Patients undergo anal swab collection at baseline to obtain samples for anal cytology, anal human papillomavirus (HPV) typing, and other HPV-related testing (e.g., HPV viral load). Digital rectal examinations (DRE) are also performed as part of the baseline physical examination. Female patients also undergo cervical swab collection for cervical HPV testing and cytology, as well as colposcopy (if available) of the cervix and vulvovaginal region to completely assess lower genital tract HPV-related lesions. At sites where high-resolution anoscopy (HRA) is available, patients are encouraged, but not required, to have an HRA with biopsy of any visualized lesions within 30 days of collection of the swabs.

After baseline assessments, patients undergo treatment with the investigative agent according to the study protocol requirements. If study treatment continues beyond 6 months, additional anal and cervical swabs are obtained for anal and cervical HPV and cytology along with DREs every 6 months until completion of study treatment and at the final study visit. Patients may also undergo additional HRA with biopsy and/or colposcopy of the lower genital tract with biopsy (women only) at this time. Patients with an abnormal anal cytology or histology are referred for HRA per local standard of care. If HRA is not available at the treatment site, patients undergo a DRE, and those with an abnormal DRE are referred for evaluation by a surgeon.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

This study will enroll patients who are study participants on interventional AMC protocols for diseases other than HPV-associated neoplasia with an accrual goal of 15 patients or more.

Criteria

DISEASE CHARACTERISTICS:

  • Serologic documentation of HIV infection by any FDA-approved tests
  • Enrolled in an AIDS Malignancy Clinical Trials Consortium (AMC) clinical trial of any new or existing pharmacotherapeutic agent for treatment of disease other than human papillomavirus (HPV)-associated neoplasia

    • AMC study must have an accrual target of > 15 patients

PATIENT CHARACTERISTICS:

  • ECOG performance status (PS) 0-1 OR Karnofsky PS 60-100%
  • Life expectancy ≥ 3 months
  • Not pregnant or nursing
  • Patients receiving myelosuppressive therapy must meet the following criteria:

    • ANC > 1,000/μL
    • Platelet count > 50,000/μL
    • Evaluated before treatment or completely recovered from their nadir
  • Able to understand and willing to sign a written informed consent document
  • No bleeding disorder or requirement for anticoagulation that would contraindicate any biopsy of the anal canal

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00695422

Contacts
Contact: J. Michael Berry, MD 877-827-3222

Locations
United States, California
Rebecca and John Moores UCSD Cancer Center Recruiting
La Jolla, California, United States, 92093-0658
Contact: Clinical Trials Office - Rebecca and John Moores UCSD Cancer    858-822-5354    cancercto@ucsd.edu   
Principal Investigator: William Wachsman, MD         
USC/Norris Comprehensive Cancer Center and Hospital Terminated
Los Angeles, California, United States, 90089-9181
UCLA Clinical AIDS Research and Education (CARE) Center Recruiting
Los Angeles, California, United States, 90095-1793
Contact: Ronald T. Mitsuyasu, MD    310-557-1893    rmitsuya@mednet.ucla.edu   
Principal Investigator: Ronald Mitsuyasu, MD         
UCSF Helen Diller Family Comprehensive Cancer Center Recruiting
San Francisco, California, United States, 94115
Contact: Clinical Trials Office - UCSF Helen Diller Family Comprehensi    877-827-3222      
Principal Investigator: J M Berry, MD         
United States, Hawaii
Cancer Research Center of Hawaii Terminated
Honolulu, Hawaii, United States, 96813
United States, Massachusetts
Beth Israel Deaconess Medical Center Recruiting
Boston, Massachusetts, United States, 02215
Contact: Clinical Trials Office - Beth Israel Deaconess Medical Center    617-667-9925      
Principal Investigator: Ayad Hamdan, MD         
Boston University Cancer Research Center Recruiting
Boston, Massachusetts, United States, 02118
Contact: Clinical Trials Office - Boston University Cancer Research Cen    617-638-8265      
Principal Investigator: Timothy Cooley, MD         
United States, New York
Memorial Sloan-Kettering Cancer Center Recruiting
New York, New York, United States, 10065
Contact: Mark Dickson, MD    212-639-5218    dicksonm@mskcc.org   
Principal Investigator: Mark Dickson, MD         
United States, Texas
Baylor University Medical Center - Houston Recruiting
Houston, Texas, United States, 77030-2707
Contact: Elizabeth Y. Chiao, MD, MPH    713-798-8070      
Principal Investigator: Elizabeth Chiao, MD         
United States, Washington
Benaroya Research Institute at Virginia Mason Medical Center Recruiting
Seattle, Washington, United States, 98101
Contact: Clinical Trials Office - Benaroya Research Institute    206-583-6526      
Principal Investigator: David Aboulafia, MD         
Sponsors and Collaborators
AIDS Malignancy Clinical Trials Consortium
The EMMES Corporation
Investigators
Principal Investigator: J. Michael Berry, MD University of California, San Francisco
  More Information

Additional Information:
No publications provided

Responsible Party: AIDS Malignancy Clinical Trials Consortium
ClinicalTrials.gov Identifier: NCT00695422     History of Changes
Other Study ID Numbers: AMC-058, U01CA121947, CDR0000590397
Study First Received: June 7, 2008
Last Updated: September 16, 2014
Health Authority: United States: Federal Government
United States: Institutional Review Board

Keywords provided by AIDS Malignancy Clinical Trials Consortium:
high-grade squamous intraepithelial lesion
low-grade squamous intraepithelial lesion
human papilloma virus infection
AIDS-related diffuse large cell lymphoma
AIDS-related diffuse mixed cell lymphoma
AIDS-related diffuse small cleaved cell lymphoma
AIDS-related immunoblastic large cell lymphoma
AIDS-related Kaposi sarcoma
AIDS-related lymphoblastic lymphoma
AIDS-related malignancies
AIDS-related peripheral/systemic lymphoma
AIDS-related primary CNS lymphoma
AIDS-related small noncleaved cell lymphoma
multicentric Castleman disease
HIV Infections

Additional relevant MeSH terms:
Communicable Diseases
Infection
Lymphoma
Neoplasms
Papillomavirus Infections
Precancerous Conditions
Sarcoma
DNA Virus Infections
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms by Histologic Type
Neoplasms, Connective and Soft Tissue
Tumor Virus Infections
Virus Diseases

ClinicalTrials.gov processed this record on November 20, 2014